We are live on ! Find out more
ABVC icon

ABVC BioPharma
ABVC

9 hedge funds and large institutions have $521K invested in ABVC BioPharma in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
9
Holders Change
+9
Holders Change %
–
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$203K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$141K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$115K
4
Squarepoint
Squarepoint
New York
+$54.4K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$42.7K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$165K +$203K +7,156 New
Geode Capital Management
2
Geode Capital Management
Massachusetts
$115K +$141K +4,992 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$94K +$115K +4,056 New
Squarepoint
4
Squarepoint
New York
$44K +$54.4K +1,921 New
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$35K +$42.7K +1,508 New
VF
6
Virtu Financial
New York
$32K +$39.3K +1,389 New
CS
7
Credit Suisse
Switzerland
$27K +$33.2K +1,171 New
TRCT
8
Tower Research Capital (TRC)
New York
$8K +$9.88K +349 New
Bank of America
9
Bank of America
North Carolina
$1K +$1.39K +49 New

ABVC Hedge Fund Activity: Q3 2021 in Review

9 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q3 2021, worth a combined $521K.

Buyers outnumbered sellers: 9 funds opened new ABVC positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $203K.

  • 9 institutional investors held ABVC BioPharma (ABVC) as of Q3 2021, up from 0 in Q2 2021.
  • Funds reported $521K of ABVC BioPharma stock for Q3 2021.
  • 9 funds opened new ABVC BioPharma positions in Q3 2021 and 0 closed out, a net change of +9 holders.
  • The largest ABVC BioPharma buyer in Q3 2021 was Sabby Management, an estimated $203K added.

Based on aggregated 13F filings for Q3 2021.